Differentiated Thyroid Cancer Patients Treated With Different Doses of Radioactive Iodine.

Launched by ASSIUT UNIVERSITY · Nov 15, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how different doses of radioactive iodine (RAI) can be used to treat patients with differentiated thyroid cancer, which includes types like papillary and follicular thyroid cancer. The study aims to understand how often doctors use single or multiple doses of RAI, how these doses affect treatment outcomes, and how living with thyroid cancer impacts the quality of life for patients.

To participate in this trial, you need to have had surgery to remove your thyroid (called a total thyroidectomy), with or without additional surgery to remove lymph nodes. It’s important that your medical records are available for review. The trial is not yet recruiting participants, but once it begins, those eligible will have the opportunity to contribute valuable information that could help improve treatment for thyroid cancer in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • • Patients with differentiated cancer thyroid either papillary or follicular underwent total thyroidectomy with or without lymph node dissection.
• • Available data of patients' records.
• Exclusion Criteria:
• • • Missed follow up data.